HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?
Authors:
Open Access
- 23 November 2014
- journal article
- review article
- Published by Springer Nature in Annals of Hematology
- Vol. 94 (1) , 1-12
Abstract
Statins have been shown to possess properties that go beyond their lipid-lowering effects. These agents act on the mevalonate pathway and inhibit synthesis of cholesterol, geranylgeranyl pyrophosphate, and farnesyl pyrophosphate, which are necessary for posttranslational modification of the Rho, Rac, and Ras superfamily of proteins. Early phase studies have demonstrated that this modulation of cellular signaling can ultimately exert pro-apoptotic, anti-angiogenic, and immunomodulatory effects, and might even restore chemosensitivity in several hematologic cancers. Nonetheless, these promising preclinical results have not yet migrated from the bench to the bedside as their effectiveness as adjuvant agents in hematologic malignancies is currently uncertain. In the present review, we summarize the existing evidence stemming from preclinical and clinical studies pertaining to the use of statins as adjuvant therapies in hematologic malignancies, and discuss the new insights gained from the ongoing translational research.Keywords
This publication has 98 references indexed in Scilit:
- Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myelomaAnnals of Hematology, 2011
- Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cellsAnnals of Hematology, 2010
- Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevanceBMC Cancer, 2010
- Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab EraJournal of Clinical Oncology, 2010
- Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20PLOS Medicine, 2008
- Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-κB pathwayBiochemical Pharmacology, 2008
- Use of statins and risk of haematological malignancies: a meta‐analysis of six randomized clinical trials and eight observational studiesBritish Journal of Clinical Pharmacology, 2007
- Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 studyBlood, 2006
- HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosisLeukemia, 2002
- Regulation of the mevalonate pathwayNature, 1990